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Abstract
The multifunctional neuropeptide Cocaine and Amphetamine Regulated Transcript (CART) is secreted from hypothalamus,
pituitary, adrenal gland and pancreas. It also can be found in circulatory system. This feature suggests a general role for
CART in different cells. In the present study, we demonstrate that CART protects mitochondrial DNA (mtDNA), cellular
proteins and lipids against the oxidative action of hydrogen peroxide, a widely used oxidant. Using cis-parinaric acid as a
sensitive reporting probe for peroxidation in membranes, and a lipid-soluble azo initiator of peroxyl radicals, 2,29-Azobis(2,4-
dimethylvaleronitrile) we found that CART is an antioxidant. Furthermore, we found that CART localized to mitochondria in
cultured cells and mouse brain neuronal cells. More importantly, pretreatment with CART by systemic injection protects
against a mouse oxidative stress model, which mimics the main features of Parkinson’s disease. Given the unique molecular
structure and biological features of CART, we conclude that CART is an antioxidant peptide (or antioxidant hormone). We
further propose that it may have strong therapeutic properties for human diseases in which oxidative stress is strongly
involved such as Parkinson’s disease.
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Introduction
The neuroendocrinesystem plays a primary role inthe regulation
of major physiological processes such as development, growth,
metabolism, reproduction, and adaptation to the environment via
peptide and steroid hormones, neurotransmitters and their
receptors [1–4]. The neuropeptide, cocaine- and amphetamine-
regulated transcript (CART) gene was first cloned in 1995 [5].
CART has been implicated in a variety of physiological processes,
including food intake, reward and endocrine regulations [6,7].
CART knockout (KO) mice have been found to display some aging-
associated symptoms, including increased body weight. In humans,
a mutation in the CART gene has been found in an obese family
[8,9]. Interestingly, a recent report showed that CART levels within
cerebrospinal fluid were significantly reduced by 30% in DLB
(dementia with Lewy bodies) patients compared to normal controls
aswell astoAlzheimer’sdisease patients[10].ThepresenceofLewy
bodies is considered to be the neuropathologic hallmark of
Parkinson’s disease (PD), one of the most common neurodegener-
ative diseases caused by degeneration of dopaminergic neurons in
substantia nigra (SN) [11].
In the center nervous system CART is widely expressed in
different tissues and regions, including cortex, midbrain and spinal
cord [12–14]. Increasing studies have shown putative anatomical
and functional network between the CART-containing neurons
and the mesolimbic dopaminergic system [9,15–18]. The network
connecting the SN, nucleus accumbens (NA), and dorsal striatum
as well as ventral tegmental area (VTA) is mainly involved in
dopaminergic motor pathways, suggesting that CART has the
capacity to modulate mesolimbic dopamine, which could have
implications for the treatment not only of psychostimulant abuse
but also for the treatment of other disorders with midbrain
dopamine involvement, such as PD.
Furthermore, CART is highly expressed in the mammalian and
human hypothalamus, pituitary and adrenal gland (HPA axis), as
well as in the circulatory system [7,12,19] (Figure S1). This feature
indicates a possible role for CART in stress and natural
homeostasis, including the cellular defense system. Interestingly
CART expression is regulated by stress in a regionally and time
specific manner, and CART is also regulated by corticosteroid
actions in the brain, including the hippocampus [9,20]. Although
much is known about CART in terms of its structure, expression
and function, little is known about CART receptors and its other
interaction proteins, which has hampered basic studies and clinical
investigations [7,21].
Recently using yeast two-hybrid screening, for the first time we
identified the mitochondrial protein succinate dehydrogenase,
subunit B (SDHB) as the first CART binding partner [22]. SDHB
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29343is a critical enzyme for both the Krebs cycle and the mitochondrial
electron transport chain (ETC), where it is known as complex II.
Furthermore, we found that CART could stimulate the activities
of SDH and complex II under basal condition and ischemic
condition (oxygen-glucose-deprivation, OGD) and preserve ATP
levels after OGD in rat primary neurons [22]. Notably a recent
report showed that only one SDHB gene mutation caused severe
clinical phenotypes in a young patient including multiple system
disorders, such as paraganglioma, type 2 diabetes, ischemic stroke,
renal failure and congestive heart failure [23]. This further
highlights the potential importance of SDHB and CART in
pathways compromised in inherited genetic diseases. In addition, a
significant common pathological feature of these disorders is
oxidative damage. However whether CART has an antioxidant
activity is unknown. Thus, in this report we investigated the
hypothesis that CART plays a protective role in the oxidative
stress using in vitro and in vivo systems. Interestingly, our data
demonstrate that CART peptide is a strong antioxidant and it may
be a potential therapeutic candidate for Parkinson’s disease.
Results
TAT-EGFP-CART protein is an effective CART molecule
In order to increase CART delivery into human cells, we first
expressed a CART fusion protein, in which CART is fused with
an intracellular transduction vector TAT-EGFP. The plasmid was
confirmed by DNA sequencing, and purified TAT-EGFP-CART
fusion protein was recognized by a CART-specific antibody using
Western blot analysis (Figure S2).
The disulfide bond of many proteins is important for their
physiological functions, and it can be chemically altered. To verify
that such unique feature of CART peptide is preserved in the
CART fusion protein, we treated TAT-EGFP-CART protein and
the vector protein TAT-EGFP with or without dithiothreitol
(DTT) and labeled all proteins with 4-acetamido-49-maleimidys-
tilbene-2,29-disulfonic acid (AMS), then subjected it to an SDS-
PAGE. As shown in Figure S3, TAT-EGFP has no significant
band shift between proteins treated and untreated with DTT,
however TAT-EGFP-CART has an increased molecular weight
comparing untreated TAT-EGFP-CART, indicating that the 3
disulfide bonds (6 systeine residues) of CART, the putative CART
peptide feature, exist in the CART fusion protein.
Since CART binds to SDHB and stimulates the activity of the
SDH/complex II [22], we further tested whether the fusion
protein TAT-EGFP-CART retained the properties of CART. As
presented in Figure S4, pretreatment of cultured cortical neurons
with TAT-EGFP-CART prevents complex II dysfunction after
OGD. However, pretreatment with TAT-EGFP protein alone
(OGD + vehicle) does not alter complex II activity, suggesting that
the effect is specifically linked to CART. Therefore, TAT-EGFP-
CART appears to function as effectively as CART peptide alone.
CART protects cellular mtDNAs, proteins and lipids from
oxidative damage
Free radicals yield more extensive damage in mtDNA than in
nuclear DNA [24–27]. To measure the damage of cellular
mtDNA, we first simplified a long template PCR method without
using isotopes [25]. DNA lesions resulting from oxidative damage,
such as strand breaks and base modifications, block the
progression of the polymerase reaction resulting in a decreased
amplification of a target sequence. As shown in Supporting
Information, the 16.2-kb mitochondrial fragment was successfully
amplified in each lane, and H2O2 treatment reduced the
amplification (Figure S5, lanes 3 and 4), especially after 1 h
100 mM treatment, the band density was 22% of normal control.
This indicates that mtDNA was significantly damaged following
1 h of H2O2 treatment. To confirm the PCR products were truly
from the mitochondrial genome, we sequenced the PCR products
with mitochondrial DNA-specific primers, the results showed that
the products were identical to the human mtDNA.
We then evaluated the effect of CART on H2O2–induced
mtDNA damage. H2O2 treatment combined with TAT-EGFP
dramatically reduced mtDNA amplification (Figure 1A, lane
H2O2+Vehicle), showing a similar result with H2O2 described
above (Figure S5). However, pretreatment with the CART fusion
protein inhibited the damaging effect of H2O2 (Figure 1A: lane
H2O2+CART).
To determine the extent of CART protection on oxidative
damage we analyzed its effect on protein oxidation by Western blot
using the primary antibody against dinitrophenylhydrazine (DNP).
As expected, H2O2 increased protein oxidation (Figure 1B, lane
H2O2+vehicle), pretreatment with TAT-EGFP-CART remarkably
reduced protein oxidation (Figure 1B, lane H2O2+CART).
Because damage to mtDNA was extensive (Figure 1A) we next
assessed the physiological state of the mitochondrion in cells
treated with H2O2 and CART. The tetrazolium salt (MTT)
method is widely used to measure cell viability. MTT reduction is
carried out mainly by mitochondrial SDH, the complex II of the
respiratory chain, thus MTT assay reflects SDH activity and
mitochondrial function [25]. When HEK293 cells were exposed to
H2O2 for 60 min, a significant decrease in MTT reduction was
observed; in other words, H2O2 treatment induced HEK293 cell
death (Figure 1C, bar H2O2). Therefore, a 60-min exposure to
H2O2 was sufficient to not only induce extensive mtDNA damage,
but also to disrupt mitochondrial function and induce cell death.
Consistent with its protective effect on mtDNA damage and the
complex II assay (Figure S4), TAT-EGFP-CART (Fig. 1C: TEC)
provided statistically significant protection against H2O2 induced
cell death (P,0.05); however, TAT-EGFP (TE) did not show any
significant effect. These data also demonstrate that CART
stimulates SDH/complex II activity and preserves mitochondrial
function in H2O2 mediated oxidative stress.
There are increasing correlations between age-related human
diseases and oxidative stress processes such as lipid peroxidation.
Lipids are the basic components of cell membranes and their
oxidative products, especially 4-hydroxyalkenals (4-HNE), initiate
structural and functional damage of cells, and increase membrane
permeability to ions such as Ca
2+ [28]. In addition, systemic
oxidative stress occurs in some neurodegenerative diseases
including PD [29,30]. Since CART is found in the circulatory
system we determined if CART also has an effect on blood cells.
Interestingly, the results of mtDNA in HEK cells (Figure 1A) were
confirmed by using template DNA isolated from human
lymphocytes (Figure 2A) in which CART treatment blocked
H2O2 induced mtDNA damage while no protective effect was seen
with TAT-EGFP alone.
To further understand the antioxidant efficacy of CART in
human lymphocytes, we measured the accumulation of mal-
ondialdehyde (MDA) and 4-HNE as markers of lipid peroxidation.
As shown in Figure 2B, H2O2 induced the generation of MDA
and 4-HNE in all groups. Compared to TAT-EGFP (vehicle), total
MDA and 4-HNE levels were significantly reduced by TAT-
EGFP-CART treatment (CART) for both doses of fusion protein
(4 and 8 mg, both P,0.05). These data further indicate an anti-
oxidative role for CART in human cells.
To understand the change of mitochondrial function in human
lymphocytes, we measured cellular ATP levels in cultured
lymphocytes by using the CellTiter-Glo Luminescent Assay.
CART Is a Novel Antioxidant
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ment markedly increases ATP levels (Figure 2C). This assay also
faithfully reflects more sensitive ATP-based cell viability suggesting
that CART dramatically increases survival of lymphocytes against
H2O2-induced cell damage.
CART preferentially localized in mitochondria in live HEK
cells and cultured primary neurons
Since mitochondria are the main cellular source of oxidants, an
antioxidant agent is predicted to be localized to the mitochondria.
To test this hypothesis, localization of a TAT-EGFP-CART fusion
protein was first examined in live HEK 293 cells using confocal
microscopy and MitoTrackor as the mitochondrial indicator. We
found extensive colocalization of TAT-EGFP-CART with mito-
chondria (Figure S6, upper panel). The signal is dispersed and
substantially reduced in the control cells (Figure S6, bottom panel).
These data are consistent with previous reports indicating that
TAT-EGFP could be rapidly transduced into cells and mitochon-
dria, but would not accumulate there [31], addressing a concern
about whether CART binding to mitochondrial SDH alters TAT-
EGFP affinity with mitochondria. Confocal microscopy revealed
that only TAT-EGFP-CART co-localized with MitoTrackor
(Figure S6), and TAT-EGFP only transiently and rarely associates.
Similarly, the co-localization of CART and mitochondria was
also seen in cultured primary cortex neuronal cells (Figure 3,
upper) and hippocampal neuronal cells (Figure 3, lower).
Endogenous CART was strongly expressed in neuronal cell body,
axon and dendrite, interestingly the mitochondria indicator
MitoTracker also strongly detected in the same areas of neuronal
cells, demonstrating that CART is localized in mitochondria in
cultured neurons.
CART localized in mitochondrial outer and inner
membranes in mouse brain
As mentioned above, CART is highly expressed in nucleus
accumbens [7,14], to further understand the location of native
CART in mouse brain, we performed an immunohistochemical
study in the nucleus accumbens using electron microscopy. As
shown in Figure 4, CART can be found in dendrites, the neuronal
cell body, and especially in the nerve terminal (NT). Notably
CART labeling is found around the outer mitochondrial
membrane. Only in CART-labeled structures are the mitochon-
dria also labeled for CART, showing the specificity of the CART
labeling. To our knowledge, this is the first evidence that the
CART peptide could be localized to the mitochondria in human
cultured cells, mouse primary neurons and mouse brain tissue.
This is a novel and important feature of CART peptide as a
potential antioxidant since the mitochondrial organelle is the
major source of cellular toxic oxidants.
Direct antioxidant role of CART
CART significantly reduced H2O2-induced cellular damage as
described above. At least partially, this may be due to the
interaction between CART and SDH [22]. In addition to this
Figure 1. CART reduces oxidative damage in HEK293 cells. (A) CART protects mitochondrial DNA damage induced by H2O2. Total DNA was
isolated from HEK293 cells following treatments. Mitochondrial DNAs were amplified by Long PCR. Marker, 1 kb ladder. (B) CART reduces hydrogen
peroxide-oxidized proteins. Proteins were damaged by reactive oxygen species (H2O2), vehicle treatment had no effect. However CART fusion protein
(TEC 5 mg/ml) decreased the oxidative damage. (C) CART diminishes cell death induced by hydrogen peroxide. Cell viability was monitored by
mitochondrial function assayed by MTT reduction: H2O2 (0.1 mM) caused a decline of cellular MTT reduction, and CART treatment, but not vehicle,
significantly increased MTT metabolism. *, P,0.05, comparing with H2O2 group, n=6.
doi:10.1371/journal.pone.0029343.g001
CART Is a Novel Antioxidant
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reactive oxygen species (ROS).
To investigate the direct antioxidant property of CART, we
used a fluorescent polyunsaturated fatty acid, cis-parinaric acid
(cisPA) as a sensitive and reliable reporting probe for peroxidation
in membranes. Attenuation of its fluorescence is a good index of
the oxidative stress at the site where cisPA is present. Thus, we
used this assay for testing CART’s properties against peroxyl
radicals, major oxygen free radicals that damage biomembranes.
This method has previously been used to investigate the
antioxidant activity of Vitamin E, ubiquinol 10, MitoQ, etc.
[32,33]. As shown in Figure 5A, incubation of mitochondria
isolated from human dopaminergic neuroblastoma SH-SY5Y cells
with cisPA and 2,29-Azobis(2,4-dimethylvaleronitrile) (AMVN), a
lipid-soluble azo initiator of peroxyl radicals caused cisPA
fluorescence decay. Interestingly, 1 nM of CART dramatically
reduced the fluorescence decay, demonstrating that CART is an
antioxidant. Additionally, the reaction of scavenging oxidants by
CART was very fast; we could detect the fluorescence increase
within 2 min after addition of the CART peptide. The speed of
this effect implies an immediate activity by CART, and suggests
that it is not dependent on a signaling cascade of antioxidant
gene/protein expression.
Very interestingly, low dose (1 nM) of CART shows an
antioxidant activity. This may indicate that CART is a strong
antioxidant. To further confirm this feature, we also investigated
the antioxidant efficacy of CART in HEK293, non-neuronal cells.
As shown in Figure 5B, a similar result was obtained. AMVN
induced cisPA fluorescence (Control) decay; however, CART
treatments (from 1 nM to 20 nM) prevented the fluorescence
decrease in a dose-dependent manner, and 20 nM of CART in
Figure 2. CART antioxidant role in human lymphocytes. (A) CART protects mitochondrial DNA damage induced by H2O2. MtDNAs were
amplified by Long PCR as described in Fig. 1. (B) CART reduces the levels of lipid peroxidation end products. Protein extracts from lymphocytes
treated with 4 and 8 mg TATEGFP-CART were compared to TATEGFP following H2O2 treatment. Total MDA and HNE formation was detected using
4 mg of total cell homogenates as starting material. Absorbance was measured at 586 nm and data are mean6SEM of 4 independent experiments.
*, P,0.05, comparing to vehicle group. (C) CART preserves cellular ATP production in human lymphocytes. Cultured cells were pretreated with
vehicle or CART fusion protein (5mg/ml) and then treated with H2O2 (0.1 mM) to induce cell death. Cell viability assay performed using a sensitive
ATP-based detection method is also an indicator of ATP levels. *, P,0.01, comparing to vehicle group, n=4.
doi:10.1371/journal.pone.0029343.g002
Figure 3. Mitochondrial localization of CART in primary
neuronal cells. Mouse cortex neurons (upper panel) and hippocampal
neurons (bottom panel) at 7-day in vitro were incubated with
MitoTracker Red. The cells were fixed and incubated with a CART
specific antibody and secondary antibody, finally treated with tyramide-
conjugated fluorescent dye Alexa 488 (green) and photographed using
a fluorescence microscope at 1006 magnification. (A) shows CART
antibody staining (green), (B) shows mitochondrial staining (red), and
(c) is merged image (yellow), demonstrating the co-localization of CART
and mitochondria.
doi:10.1371/journal.pone.0029343.g003
CART Is a Novel Antioxidant
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Based on these results, we propose that CART is an antioxidant
that efficiently inhibits AMVN-induced oxidation of cisPA.
Antioxidant role of CART in vivo
As an antioxidant CART may have clinical significances, thus
we examined the antioxidant outcome of CART peptide in vivo.
Importantly, PD and its mouse model are dopamine neuron
degenerative disorders, in which mitochondrial (especially com-
plex I) dysfunction and oxidative stress have been strongly
implicated [29,34,35]. The neurotoxin, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) mainly impairs complex I,
produces oxidative damage in the substantia nigra, results in
dopamine neuronal degeneration and parkinsonian symptoms in
several species including human, non-human primate and mouse
[28,29,36]. Thus, we investigated the effect of CART on tyrosine
hydroxylase (TH) labeled neurons in the substantia nigra pars
compacta (SN-PC) following administration of MPTP to C57BL/
6J mice [37,38]. In addition, motor behavioral tests on the animals
were also performed.
The results of TH immunolabeling in the SN-PC for each group
are summarized in Figure 6. A two-way ANOVA (analysis of
variance) revealed significant differences between groups
(Figure 6A and 6B, P,0.0001). Seven days after the first injection
of the neurotoxin, post-hoc analysis revealed there was a
significant decrease (31%) in the mean number of TH-immuno-
labeled neurons/section in the SN-PC in the sub-acutely MPTP-
treated group compared to the vehicle-treated group (CTL)
(Figure 6, P,0.001). This decrease in TH-labeling was similar to
previous reports on the relative optical density of the SN-PC
following sub-acute MPTP exposure [37,38]. Interestingly, the
decrease in TH-labeled neurons in the MPTP group was
completely blocked by pretreatment with intraperitoneal injection
(50 ng/mouse) of CART peptide (Figures 6A and 6B). These in
vivo data strongly support our in vitro findings, indicating CART
also has antioxidant and neuroprotective roles in vivo.
To determine the effect of CART against MPTP induction on
mice behavior, we used the rearing behavioral test that counts the
number of times the mouse rears in a cylinder over a 5 minute
period and whether the mouse uses the wall to rear or rears free in
Figure 4. Mitochondrial localization of CART in mouse brain. In
the mouse nucleus accumbens determined by electron microscopy. The
dark diaminobenzidene reaction product shows that CART is located in
a nerve terminal (NT) making a symmetrical synaptic contact (arrow)
onto a neuronal cell body. Within the NT is a mitochondrion in which
there is CART labeling (arrowheads) around the outer and the inner
mitochondrial membranes. Within the photograph is a CART-labeled
dendrite (DEND) in which there is a mitochondrion showing CART
labeling, particularly along the outer mitochondrion membrane
(arrowheads). Magnification: 640,000.
doi:10.1371/journal.pone.0029343.g004
Figure 5. Radical scavenging role of CART. (A) Effects of CART on AMVN-induced fluorescence decay in mitochondria isolated from human
SHSY cells. AMVN 1.5 mM was added to the reaction medium (0.2 ml) containing mitochondria 50 mg, cis PA 12 mM in 0.1 M KCl and phosphate
buffer (50 mM, pH 7.4 at 40uC). CART (1 nM) was added 20 min later. The fluorescence intensity was monitored by using a BIO-TEK
spectrofluorometer. (B) Radical scavenging activity of CART in mitochondria isolated from HEK293 cells. The reaction containing 50 mg mitochondria,
cisPA 6 mM, CART peptides and AMVM 2 mM in 0.1 M KCI and phosphate buffer was performed at 40uC for 20 min, and the fluorescence intensity
was measured after continued incubation at RT for 90 min. *, P,0.05; **, P,0.01; ***, P,0.001, comparing with AMVM group.
doi:10.1371/journal.pone.0029343.g005
CART Is a Novel Antioxidant
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50 split between the percent free versus wall assisted rears [39]. In
the MPTP group, with loss of dopamine there is a decrease in the
number of free rears, meaning the mouse uses the wall more often
to assist in rearing. A two-way ANOVA revealed significant
differences between groups (Figure 7A, P,0.003). CART was able
to reverse the MPTP-induced decrease in the percentage of free
rears effects due to MPTP alone (Figure 7A, P,0.01). This
reversal was associated with the recovery in TH-immunoreactive
cells in the SN-PC (Fig. 6). In contrast, wild-type mice treated with
CART showed a possible side-effect in this behavioral assay
(Figure 7A), indicating normal animals that already have
endogenous CART do not need additional CART, which may
adversely affect their locomotor behavior. To this point, we
propose the use of CART as a therapeutic agent only for PD
patients, not for healthy individuals.
To further investigate the alterations in motor behavior, we
used a foot-fault test to measure the number of times there was a
slip of the paw (either forepaw or hindpaw) through this parallel
bar apparatus [39]. When the paw touches the metal floor beneath
the parallel bars, the number of such faults is counted. A two-way
ANOVA revealed significant differences between groups
(Figure 7B, P,0.016). The results demonstrate that with MPTP,
there was an increase in the number of foot-faults and that CART
was able to block this affect (P,0.02 between the MPTP and
MPTP/CART groups, Figure 7B). This behavioral task further
confirmed that CART is protective in this PD mouse model.
Discussion
In the present study we further demonstrated that CART
peptide could enter mitochondria and has an important primary
function as an antioxidant. Because of the importance of cellular
mitochondria, these findings have shed new light on the mole-
cular mechanisms of CART and its therapeutic possibility for
some mitochondria-related diseases, especially neurodegenerative
disorders.
General cellular protection of CART against oxidants
Oxidative stress occurs as a result of an imbalance between the
production of ROS and the cell’s capacity to neutralize them
through its intrinsic antioxidant defenses. Oxidative damage
accumulates in normal aging and is involved in the pathogenesis
of several neurodegenerative diseases, diabetes, stroke, and cancer
[34,40,41]. Mitochondria are thought to play a crucial role in the
aging process and disease development not only due to their role
as the main intracellular generators of ROS, but also because they
are targets of ROS attack. An increased production of ROS or a
poor antioxidant defense network can lead to progressive cell
damage with a decline in physiological function. Consistent with
previous reports, our results also revealed that excessive ROS
(H2O2) can damage cellular protein, lipids and DNA, especially
mtDNA. Further, our study is the first report that peptide CART
significantly reduces the oxidative damage of mtDNA, cellular
proteins and lipids in human cells, and directly scavenges ROS.
Interestingly, CART’s role against oxidative stress is likely stronger
than many known antioxidants such as mitoQ, for example, 2 nM
of CART were similar to 20 nM of mitoQ in cultured cells
[33,42]. Other antioxidants, such as vitamin C [43], and
melatonin [44,45], were also well studied at pharmacological
levels, the doses used in these studies were however mostly higher
or much higher than what we used in this CART study.
In addition, CART reduces the neurotoxin/oxidative stress-
induced decrease in TH-labeled neurons present in an in vivo
model of PD, in which oxidative stress is strongly involved,
Figure 6. Effect of CART on the number of TH-labeled neuronal cells in the SN-PC. A.) Example of TH-immunolabeled neurons within the
SN-PC in all four groups: CTL: control group (vehicle + vehicle); CART (CART + vehicle); MPTP (vehicle + MPTP); MPTP/CART (CART + MPTP). There is a
decrease in the number of TH-labeled cells in the MPTP only group compared to all other groups. Administration of CART reversed the MPTP-induced
decrease in TH-labeled cells. B.) CART peptide (50 ng/mouse, IP) or vehicle (0.1 ml/10 grams, IP) was injected one day prior to the start of sub-acute
administration of either MPTP (7 mg/kg/d) or vehicle for 7 days. On days 1–7, CART or vehicle were injected 30 minutes prior to administration of
either MPTP or vehicle. On day 8, mice were perfused with fixative and the SN-PC cut and processed for TH immunolabeling. CART pretreatment
blocked the MPTP-induced decrease in the number of TH labeled cells/section of the SN-PC. *, p,0.05 compared to all other groups.
doi:10.1371/journal.pone.0029343.g006
CART Is a Novel Antioxidant
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hopeful therapeutic agent for some human diseases.
Our previous study showed that CART significantly improved
neuronal survival in primary cortical neuronal cells cultured under
OGD condition, an in vitro ischemia model in which ROS plays a
major role [22]. Mitochondiral complex II is thought to be an
essential player in hypoxic ROS production [22,30,46]. These
results are consistent with recent reports [47–49] that CART
peptide promotes the survival of neuronal cells, including
hippocampus and enteric neurons. Interestingly, a neuroprotective
roleof estrogen is also mediated by CART [48]. Taken together, we
propose that CART has a general cellular protective role in
mammalian and human cells, at least in part, through its
mitochondrial mechanisms, particularly via anti-oxidative function.
CART as an antioxidant hormone and the mechanisms of
its action
Studies have shown that neuroendocrine peptide CART is
associated with multiple physiological processes, for instance,
feeding, body weight control, and response to drug abuse [6,7,9].
As described above, CART is not only highly expressed in the
hypothalamus, but also exists in the circulatory system and has a
diurnal rhythm [19]. Since these features are similar to many
hormones, we considered that CART could be a novel peptide
hormone. To date, a physiological hormone with primary antioxi-
dant properties has not been reported. Interestingly, a low dose of
CART peptide displayed a strong antioxidant activity (Figure 5).
These data are consistent with the idea that CART functions as an
antioxidant, which has been defined as ‘‘any substance that, when
present at low concentrations compared to those of an oxidizable
substrate, significantly delays or prevents oxidation of that substrate’’
[50]. Hence, CART should be considered as a novel antioxidant
peptide or antioxidant hormone (AOH).
CART contains three disulfide bridges in its C-terminal part;
that seems to form a new unique structure not found in any other
proteins [51]. Further, we recently did a database search to find
other peptides of similar molecular weight, cysteine numbers and
disulfide bonds as CART. However, we were unsuccessful finding
such peptides. To date, CART appears to be a new type of
peptide. A typical antioxidant such as glutathione, a low molecular
weight thiol-containing compound in living cells, should have a
reduced form (GSH), which can converted to oxidized form
Figure 7. Effect of CART on motor behavior. (A) Percent free rears. The number of free versus wall-assisted rears was counted over a 5-minute
period on day 8 after the last of the MPTP/CART/vehicle injections and the results presented as percent free rears. For the Control (CTL) group, there
was nearly a 50/50 split in terms of the number of free versus wall-assisted rears. There was a decrease in the percent free rears for the CART only
group, which was equivalent to that seen in the MPTP treated group. CART pretreatment reversed the MPTP-induced decrease in free rears to the
levels seen in the control group. *, p,0.05 compared to the CTL and MPTP/CART groups. (B) Number of foot-faults. The number of foot-faults during
a 5-minute period was determined on day 8 after the last of the MPTP/CART/vehicle injections. CART pretreatment, then followed by MPTP, resulted
in a significant decrease in the number of foot-faults compared to the MPTP only group. *, p,0.05 compared to the MPTP group. (C) Schematic of
mechanisms of CART action. Based on our data, CART peptide functions through at least two different and associated pathways, interaction with
mitochondrial SDH and directly scavenging oxidants, ultimately preserving cells/neurons.
doi:10.1371/journal.pone.0029343.g007
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and free radicals, thus protecting the cells against oxidative
damage. Similarly, CART has conformational changes between 6
cysteines (S–H) and 3 disulfides (S–S) bonds (Figure S3). This
combined with the mitochondrial localization (Figure S6, and
Figures 3 and 4), classifies CART as an AOH, Anti-Oxidative
peptide Hormone. The molecular structure also indicates that
CART belongs to the family of small thiols. A primary role of
small thiols may be one of defense systems against oxidants and
other deleterious compounds [52]; our finding regarding the
antioxidative properties of CART is consistent with this idea.
Therefore we consider the antioxidant role of CART as its
primary function.
In the current study we focused primarily on CART’s active
molecule, CART55-102. While we have not studied other CART
fragments, our understanding of CART structure suggests that the
antioxidant activity is conferred by the unique motif of 6 cysteine/3
disulfides. Thus, we expect that, CART 1–102 and CART 62–102
would also have the antioxidative activity. However, CART1-27 as
the leader sequence does not contain the motif and may thereby not
have the antioxidant property. More in depth characterization will
be needed to answer these questions unequivocally.
We demonstrated the direct antioxidant property of CART.
However, since we previously showed that CART has a
transcriptional role in cultured mammalian and human cells
[53], we cannot exclude gene-protein expression and signal
transduction cascade mechanisms in whole cell and in vivo. Other
studies also demonstrated that CART could increase brain-derived
neurotrophic factor (BDNF) and uncoupling protein UCP-1
expression [47,54]. As a transcriptional regulator, CART may
stimulate other antioxidant gene’s expression. This needs further
investigation. Our in vivo study showed that CART dramatically
reduced the decrease in TH-neuronal labeling induced by MPTP.
Our data also suggest that the near reversal of TH-labeling in the
SN-PC was associated with recovery of motor function, indicating
the possibility of future clinical use of CART as a novel
antioxidant peptide or hormone.
Interestingly, in situ hybridization studies combined with SDH
histochemistry and image analysis show that CART mRNA and
SDH co-localize in cerebral cortex cells [12], in which SDH is
an active metabolism enzyme marker. Using live HEK culture
cells, primary cultured neurons and MitoTracker Red, a
mitochondrion-selective dye, we first demonstrated that CART
preferentially localized into mitochondria. Furthermore, in
primary cultured neuronal cells and mouse brain section
(Figures 3 and 4), using CART specific antibodies we examined
in more detail the location of the CART peptide, and found that
native CART is also found in mitochondria, particularly along
the outer and inner mitochondrial membranes. This is an
important anatomical aspect of CART’s action related to
mitochondrial stimulation and protection. In contrast, we have
shown that presynaptic localization of other peptides (such as the
delta opioid receptor, vesicular glutamate transporters 1 and 2)
do not cluster around the mitochondria when determined by the
same approach [55–57]. The specificity of CART localization is
clearly demonstrated in the current study, where we show that in
unlabeled nerve terminals, there is no labeling of the
mitochondria. Therefore, we conclude that CART labeling of
the mitochondria in the nerve terminal is specific and it is
different from other peptides.
As shown in the published CART knockout papers [58–60] the
CART KO mice get obese easily, which combined to our data
suggests a direct link between obesity and oxidative stress.
However further work with CART KO mice including study of
their oxidative changes and status of antioxidants will be required
to fully understand these observations.
CART as a potential therapeutic target for Parkinson’s
disease and other oxidative stress-related diseases
Mitochondria are a common organelle in most mammalian
cells, where they supply the majority of the cell’s energy. Peptide
CART appears to be an endogenous stimulator that boosts
mitochondrial function through interacting with SDHB [22]. In
the current study, we show that CART can directly scavenge ROS
and exert a general cellular protection role against oxidative stress
in vitro. These observations indicate that CART may be a potential
agent for treatment of some diseases in which oxidative stress is
involved. For example, since PD is associated with reduced
respiratory capacity (as a consequence of primary complex I
deficits), increased electron leakage and oxidative stress, feeding
electrons into ETC via complex II may be protective in this
disease. In addition, CART is closely connected to dopaminergic
neurons both anatomically and physiologically [15,61–63].
Dopaminergic neurons are thought to be particularly vulnerable
to oxidative stress because they contain dopamine. Thus we chose
a common PD animal model to examine the possibility of CART
as a therapeutic antioxidant. A previous report indicates that
CART readily passes through the BBB (blood–brain barrier) after
intravenous injection [64]. However, in the current study we used
for the first time intraperitoneal injection of CART. Not
surprisingly, our observations from the reduction in the loss of
TH-labeled neurons to motor behavioral improvements in the
MPTP mouse model of PD indicate that CART can enter the
brain and exert a neuroprotective role in vivo. This further suggests
that CART may be a potential therapeutic agent for PD patients.
Clearly this concept will require further validation and additional
animal model studies including nonhuman primates before we can
completely understand CART role and function with regard to
PD. It is encouraged that some patients with neurodegenerative
diseases, such as dementia with Lewy bodies [10] have shown a
reduced level of CART in their cerebrospinal fluid, indicating the
clinical importance of this peptide and it may be a biomarker or
therapeutic target for such disease.
Based on our observations, the possible mechanisms for peptide
CART are illustrated in Figure 7C. Indeed, a main feature of age-
related diseases (such as PD) is oxidative stress, therefore CART
acts as an antioxidant to scavenge ROS, and preserves cellular
ATP, eventually slows the development of such diseases.
Interestingly, some mitochondrial-oxidative stress-related dis-
eases, such as Huntington’s disease [65] and neuroendocrine
malignancy [66], exhibit a significant increase in CART peptide
levels. The underlying mechanism is unclear, but it may reflect a
physiological or pathophysiological response of CART as an
endogenous antioxidant peptide/hormone to pathological oxida-
tive damage, rather than a biomarker for the corresponding
disease. We interpret this as an adaptive response to the oxidative
stress, and postulate it as a new basic molecular mechanism of
increased defense or tolerance to cellular oxidative stress. This
antioxidative adaptation is an important part of the body defense
system, in some cases, it happens not just locally, but also in the
circulatory system [67]. Alternatively, the adaptive changes may
be the key to treatment for some stress-related disorders [67].
Finally, in the present study, we discovered a new function of
CART, its antioxidant activity via which CART protects cellular
lipids, protein and mitochondrial DNA against oxidant stress
which suggest a general cytoprotective role for CART. A better
understanding of the mechanisms through which the antioxidant
peptide CART provides neuroprotection may uncover a novel
CART Is a Novel Antioxidant
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29343avenue for Parkinson’s disease and other neurodegenerative
disease therapeutics.
Methods
Plasmids and CART fusion proteins
CART (Residues 55–102) [5,22] and Enhanced GFP (EGFP)
cDNAs were amplified by PCR and sequenced to confirm
sequence integrity and inserted into the pTAT-2.1 vector
(provided by Dr. Steven Dowdy at UCSD). pTAT-2.1, pTA-
TEGFP and pTATEGFP-CART were transformed into E. coli
BL21(DE3), respectively. The expressions of HisTAT and
HisTAT fusion proteins were induced by 0.1 mM iso-prppyl-1-
thio-b-d-galactopyranoside (IPTG) and were purified by Ni-NTA
column (Qiagen) according to the manufacturer’s recommended
protocol and dialyzed against PBS overnight. The protein
concentration was measured by the Bradford method [22]. The
bands in the SDS-polyacrylamide gel electrophoresis (PAGE)
stained with Coomassie blue or Western blot analyzed by specific
antibody indicated the products were correct.
Cysteine labeling assay
Reactions were carried out with the purified fusion proteins,
TATEGFP 20 mg or TATEGFP 40 mg in 10 mM HEPES and
50 mM NaCl (pH 7.0) and supplemented with 0, 20, 100 mM of
DTT. All buffers in their bottles and reaction tubes were flushed
with N2. After incubation for .5h ra t3 0 uC to reach equilibrium,
reactions were quenched with the addition of cold trichloroacetic
acid (TCA) to 25% and precipitated on ice for .1 hr. The pellet
was collected by centrifugation at 13,000 g, washed with acetone
and resolubilized in 1% SDS, 200 mM Na2HPO4 (pH 7.0)
supplemented with 20 mM 4-acetamido-49-maleimidystilbene-
2,29-disulfonic acid (AMS; MW, 624.33 Da; Invitrogen). The
labeling reaction proceeded for 10 min at room temperature and
was directly loaded onto a 10% SDS-PAGE. Protein was
visualized by Coomassie staining and was imaged.
Cell line cultures and primary cultures
HEK293 cells were obtained from the American Type Culture
Collection (ATCC) maintained in DMEM supplemented with
10% FBS as previously described [22,68]. Normal and Epstein
Barr virus transformed B-lymphocytes were obtained from ATCC
and cultured at ,5610
5/mL in RPMI-1640 containing 10% FBS,
penicillin (100 units/ml) and streptomycine (100 mg/ml) in 75-cm
2
tissue culture flasks at 37uC, 5% CO2, and 90% relative humidity,
and fed periodically by replacement of one third of the medium.
Human SH-SY5Y neuroblastoma cells were also obtained from
ATCC and cultured under standard conditions in DMEM
supplemented with 2 mM L-glutamine and 10% FBS. Cultures
of cortical and hippocampal neurons were prepared as previously
described [22]. Cellular mitochondria were isolated and mito-
chondrial complex II activity assay, MTT assay and ATP assay
were performed as described previously [22]. All animal related
works were approved by our Institutional Animal Care and Use
Committees (IACUCs) and followed the NIH Guide for the Care and
Use of Laboratory Animals (NIH Publications No. 80–23, revised
1978). The approved IACUC numbers for our studies are Oregon
Health and Science University 0725, Portland VA Medical Center
3310 and 3705.
Treatment of cells with CART and H2O2
HEK293 cells 1610
6 or lymphocytes 1.5610
6 were plated in
duplicate in 60-mm dishes 24–28 hr before treatment. H2O2
(30%; Fisher) was diluted into phosphate-buffered saline (PBS) and
the concentration was determined by absorbance at 240 nm as
described [69]. Cultures were pretreated with CART (final
concentration for fusion proteins were 5 mg/ml) for 40 min and
then exposed to 100 mMH 2O2 (unless otherwise indicated) for
either 1 or 2 hr at 37uC in serum-free medium. Non-treatment
cells were mock-treated with serum-free medium alone. Cells were
washed once with PBS, harvested immediately as described below.
MtDNA damage assay with semi-quantitative long
template PCR
This method detects any DNA lesions including oxidative
damage capable of stopping a thermostable polymerase on the
DNA template. Hence when using equal amounts of DNA
template, increased DNA damages result in decreased PCR
amplification of the target sequence. HEK cells and lymphocytes
were treated by CART fusions following 100 mMo fH 2O2 for 1 h
and the total DNA was isolated by the QIAamp DNA isolation
kit (Qiagen) as described by the manufacturer. DNA isolation by
this method has been shown to be suitable for long PCR,
including mtDNA PCR [25]. Isolated DNA (100 ng) was used for
PCR amplification of mitochondrial DNA. PCR was performed
in a GeneAmp PCR 9700 with the Expand 20 kb PCR kit
(Roche) and specific human mitochondrial primers [25]
(hmtDNA forward, 59-TGAGGCCAAATATCATTCTGAGG-
GGC-39 and hmtDNA reverse, 59-TTTCATCATGCGGA-
GATGTTGGATGG-39). Briefly, an initial denaturation for
2 min at 92uC followed by 30 cycles of 93uCd e n a t u r a t i o nf o r
15 sec, 65uC annealing for 15 sec and 68uC primer extension for
12 min. A final extension at 72uC was performed for 10 min at
the completion of the profile. Amplified products (,16.2 kb) were
loaded to a 0.8% agarose gel (with ethidium bromide) and
subjected to electrophoresis, the bands were photographed and
quantitated with BIO-RAD imaging system.
Measurement of cellular protein oxidation
To determine the extent of H2O2-induced protein oxidation,
Western analysis was performed using the Oxyblot Protein
Oxidation Detection Kit (Chemicon). Near confluent monolayer
HEK293 cells pretreated with CART peptide or fusion proteins
were treated by addition of H2O2 to the medium for 2 h and
washed with PBS. The cells were scraped into lysis buffer,
collected in microcentrifuge tubes, and lysed by sonication. Cell
lysates were centrifuged (50006g, 1 min), and the resulting
supernatants were collected and the protein concentrations were
determined as above. A portion of each sample (15 mg protein) was
added to an Eppendorf tube along with 12% sodium dodecyl
sulfate (SDS, 5 ml) and dinitrophenylhydrazine (DNP) (10 ml) for
15 min to derivatize oxidized protein residues. The derivatized
samples (15 mg protein/lane) were electrophoresed on a 10%
SDS–PAGE gel. The derivatized proteins were transferred to
nitrocellulose and relative amounts of oxidized protein were
determined by Western blot analysis using the primary antibody
rabbit anti-DNP and the secondary antibody goat anti-rabbit IgG
(horseradish peroxidase conjugated).
Lipid peroxidation detection
Lipid peroxidation was measured using an LPO586 assay kit
(Oxis, Inc., Portland, OR), according to the manufacturer’s
protocol. Briefly, Lymphocytes were treated and lysed by
sonication. A 200-ml sample of each treatment was added to
650 ml of 1:3 dilution of 10.3 mM N-methyl-2-phenylindole in
acetonitrile and methanol in a test tube. After mixing by vortex,
150 ml of 15.4 M methanesulforic acid was added. Samples were
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supernatants were transferred to cuvettes and absorbance was
measured at 586 nm. The 4-HNE diethylacetal standards were
diluted in water. The blanks and standards were incubated
concurrently with assay samples. Total levels of the two
compounds 4-HNE and MDA were measured.
Cell viability assay
HEK293 cells were treated as described above and then
incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoli-
um bromide (MTT, Sigma) at a final concentration of 2.0 mg/ml
for 3 hr, lysed (20% SDS/50% dimethylformamide), and
measured at an absorbance of 570 nm. Absorbance values were
converted to MTT reduction, and cell viability was expressed as
percent control [22].
ATP production assay
To examine cellular mitochondrial function, we measured the
cellular ATP production by using a sensitive and stable CellTiter-
GloH Luminescent Assay kit (Promega). Briefly, lymphocytes were
pretreated with TATEGFP or TATEGFP-CART following
addition of H2O2 to the medium, and then 2610
4/well were
cultured for 2 h in a 96-well plate in the RPMI-1640. Equal
volume of CellTiter-Glo reagent was added to each well for
15 min and the luminescence was detected by a Viatras
luminometer.
Mitochondria localization of CART in cultured cells
(1) In live HEK cells. Cells in 6-well plates were treated with
8 mg/ml of TATEGFP-CART or TATEGFP, respectively. 24 h
after treatment the cells were incubated with 50 nM of
MitoTracker Red CMXRos (Invitrogen) according to the
manufacturer’s instructions. The cells were then washed with
PBS and fresh medium was added to the cells. Cells were subjected
to a Leica TCS SP confocal laser scanning microscopy (Leica,
Wetzlar, Germany). Images were visualized, digitally recorded and
then colorized using Adobe Photoshop. (2) In primary neuron
cells. The cortex and hippocampus of C57BL/6J mouse were
dissected and reserved for primary culture as described previously
[22,70]. Neuronal cells were cultured on cover slides for one week,
and incubated with 20 nM of MitoTracker Red CMXRos for
1 hr. The neuron cells were fixed with 4% paraformaldehyde and
incubated with CART specific antibody (Santa Cruz, 1:100)
following a biotinylated secondary antibody (1:300). Then cells
were incubated with the ABC solution (1:500 dilution, Vector
Laboratories) and treated with tyramide-conjugated fluorescent
dye Alexa 488 (green) (Invitrogen) and mounted with prolong gold
then photographed using a fluorescence microscope at 1006
magnification.
Electron microscopic immunohistochemistry
Three naı ¨ve C57BL/6J mice (Jackson Labs, Bar Harbor, ME)
were anesthetized with isoflurane, the chest cavity opened and
perfused transcardially with 3 mls of heparin (1000 units/ml) in
0.1 M PBS (pH 7.3), followed immediately by 35 ml of 1%
glutaraldehdye/0.5% paraformaldehdye/0.1% picric acid in
0.1 M PBS (pH 7.3). The brains were fixed overnight and then
cut on a vibratome at 60 mm. The tissue was incubated in a
microwave (Pelco BioWave, Ted Pella, Inc, CA) for 5 minutes,
550 watts (W), at 35 degrees C (all the remaining steps occurred at
this temperature without vacuum unless specified) in 10 mM
sodium citrate, pH 6.0, rinsed in 0.1 M PBS for 261 min at
150 W, exposed to 3% hydrogen peroxide at 150 W for 1 min,
rinsed in PBS at 150 W for 261 min, exposed to 0.5% Triton X-
100 for 5 min, 550 W with the vacuum on, washed in phosphate
buffer for 261 min at 200 W with the vacuum off, then exposed to
the primary antibody (rabbit polyclonal, 1:100; Phoenix Pharma-
ceuticals, Inc, CA) for 12 minutes at 200 W, 4 times using the
following cycle: 2 min on, 2 min off, 2 min on, 5 min off, all on a
continuous vacuum [56]. The tissue was then rinsed in phosphate
buffer, 261 min, at 150 W, then exposed to the secondary
antibody (biotinylated goat anti-rabbit, 1:500; Vector Labs, CA)
for 15 minutes at 200 W for two cycles of the following: 4 min on,
3 min off, 4 min on, 5 min off, all on a continuous vacuum. The
tissue was then rinsed in PBS, 261 min, at 150 W, then exposed
to ABC (Vector Elite Kit, 1 ml/ml of solution A and B in
phosphate buffer) for 11 minutes at 150 W, under vacuum, using
the following cycle: 4 min on, 3 min off, 4 min on. The tissue was
then rinsed in phosphate buffer, 261 min, at 150 W and exposed
to diaminobenzidene (0.5 mg/ml+1.5% hydrogen peroxide) for up
to 10 minutes. The sections were then processed for embedding in
epoxy resins as previously described [37,56]. Thin sections were
cut on an ultramicrotome (Leica Ultracut) and then viewed and
photographed at 640,000 on a JEOL 1400 electron microscope.
Digital images were captured using an AMT (Danvers, MA)
2K 62 K digital camera.
Radical scavenging assays
Mitochondria of cultured cells were isolated and measured as
previously described [22]. SH-SY5Y mitochondria (50 mg),
cisPA (cis-trans-trans-cis-9,11,13,15-octadecatetraenoic acid,
Molecular Probe, Eugene, OR) were added into 0.1 M KCl
and 50 mM PBS. The final concentration of cisPA was 12 mM.
The reaction was started by increasing the sample temperature
to 40uC immediately after the addition of AMVN (Cayman
Chemical, 1.5 mM, zero time) and CART peptide (CART55-
102, Phoenix, final concentration: 1 nM) was added 20 min
after the addition of AMVN. The measurements of fluores-
cence of cisPA were performed on a spectrofluororometer
( B I O - T E K ) e v e r y 5m i n f o r 6 0m i n . T o f u r t h e r v e r i f y t h e
scavenging role of CART in different cells, HEK cellular
mitochondria (50 mg) containing cisPA (6 mM) and different
concentrations of CART (0, 1, 10, and 20 nM) were prepared.
The reaction was started with addition of AMVN (2 mM) at
40uC for 20 min, incubation was continued at RT for 90 min,
and fluorescence intensity was then measured by the spectro-
photometer as described above.
PD mouse model and drug treatment
C57BL/6J mice (males, 10 weeks old, Jackson Labs, Bar
Harbor, Maine), were maintained on a 12 hour light/dark cycle
with continuous access to food and water. All necessary
precautions were taken in handling, injecting and disposal of
MPTP and the mouse caging material [36,37,71]. The mice were
first injected with the CART peptide (CART55-102, Phoenix,
50 ng in normal saline/mouse, IP) or vehicle (normal saline,
0.2 ml/mouse, IP). Then one day later, animals were injected with
the CART peptide or vehicle and 30 minutes later, administered
MPTP (7 mg/kg, IP) or vehicle, as previously described [39]. This
sequence of injections continued for 7 days. The following groups
were tested: control (vehicle/vehicle, n=4), CART (CART/
vehicle, n=4), MPTP (vehicle/MPTP, n=6), CART/MPTP
(n=7). One day following the last injection, and after the
behavioral testing, mice were anesthetized with isoflurane and
then perfused with 50 ml of fixative (1% acrolein/2% parafor-
maldehyde in 0.1 M PBS, pH 7.2) [37,38].
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(1) Rearing Test. One day after the last injection of drug (ie day
8), the mice were placed in the middle of a plastic cylinder (6 cm
wide615 cm deep, black colored floor) and the number of free or
unassisted rears (i.e. mice reared up without the need to support
themselves by the wall) and the number of assisted rears (i.e. mice
reared up with the need to support themselves by the wall) was
counted over a 5 minute period, as previously described [39].
There was no acclimation time prior to testing. The number of
free and assisted rears was totaled and the data presented as mean
percent of free rears. Between animal testing, the chamber was
cleaned with 10% isopropyl alcohol. (2) Foot-fault. The number
of foot-faults or slips through parallel bars over a 5 minute period
was recorded using a parallel rod floor apparatus as previously
reported [39] and tested for reliability [72]. The apparatus consists
of a 15615620-cm clear acrylic plastic box with a removable top.
The steel rods are 1.6 mm in diameter, separated from each other
by 6 mm. A stainless steel plate is set 1 cm below the rod floor.
When the mouse’s paw slips through the parallel rods and contacts
the metal plate, a circuit is closed and an error recorded by the
computer. Slips of the tail or feces through the rods are not
recorded [63]. The mice were acclimated to the testing chamber
for 5 minutes prior to the recording of the footfaults. Between
animal testing, the chamber was cleaned with 10% isopropyl
alcohol. The data are presented as the mean number of footfaults/
5 minutes.
Tyrosine hydroxylase (TH) immunolabeling
To determine the mean number of TH immunolabeled neurons
within the substantia nigra pars compacta (SN-PC) after the
treatments, following the completion of the behavioral experi-
ments, animals were anesthetized with isoflurane and perfused
with fixative (see above), washed overnight in PBS, and then cut at
70 mm using a vibratome (Leica Microsystems, Bannockburn, IL)
[39]. Sections were serially cut throughout the entire rostral/
caudal extent of the substantia nigra. Eight sections covering the
full extent of the substantia nigra were incubated in individual
wells (48 well plate) at RT for 30 minutes in 1% sodium
borohydride (in 0.1 M PBS) and then washed several times
(5610 minutes) in PBS. For antigen retrieval, the sections were
incubated in a microwave (Ted Pella, Redding, CA) for 5 minutes
in 500 ml of 10 mM sodium citrate (pH 6.0) at 550 Watts, 60uC,
with no vacuum. The tissue was washed in PBS and incubated in
the cold room (4uC) in blocking solution (5% normal goat serum,
0.5% triton X-100, in PBS) for 1 hour. The blocking solution was
then replaced with antibody [mouse anti-TH sera (Diasorin,
Stillwater, MN), diluted 1:20,000 in blocking solution] and
incubated overnight in the cold room. The sections were then
washed in PBS, followed by RT incubation in biotinylated goat
anti-mouse IgG (Vector Labs, Burlingame, CA, diluted 1:250) for
45 minutes, washed in buffer, and then exposed to avidin-biotin
complex (Elite Kite, Vector Labs, diluted per manufacturers
instructions). The sections were washed in buffer and exposed to
3,39 diaminobenzidine hydrochloride (DAB kit, Vector Labs,
diluted per manufacturers instructions). Sections were mounted
serially on gelatinized slides, left to dry overnight and then
coverslipped. Digital photographs were taken of each side of the
substantia nigra, the number of TH-labeled neurons counted and
the number of TH-positive neurons averaged between the two
sides of the brain. The number of TH-labeled neurons per section
(averaged between the two sides) of the SN-PC were averaged
between the 8 sections/animal and the overall mean number
determined for each experimental group. From these tissue section
counts, the total number of labeled neurons was re-evaluated using
the Abercrombie correction, which accounts for fragmented nuclei
within each section and provides an accurate estimate when tissue
thickness exceeds soma thickness by more than 50%, which is the
case in this study, as previously described [39]. Although this cell
counting methodology may have yielded an underestimation of
the total number of TH immunolabeled neurons/section in the
SN-PC, it is an appropriate approach for measuring the mean
number of neurons/section according to recent comparisons of 2D
and 3D analyses of brain tissue [73,74].
Statistical Analysis
Reported values are means6SEM. Observed mean differences
between controls and treated groups were analyzed by Student’s t
test. Where multiple data were compared, an ANOVA was
employed before group comparisons were made. For the mean
number of TH immunolabeled cells/section and both behavioral
measures, the differences between groups were determined using a
two-way ANOVA, with significant main effects characterized
using the Tukey-Kramer post-hoc for comparison of multiple
means. A P-value of ,0.05 was considered to be statistically
significant.
Supporting Information
Figure S1 Tissue expression of CART peptides deter-
mined by Western blot analysis. Several rat tissues were
isolated from adult female rat, 20 mg of protein was run on a
peptide gel (Invitrogen) and transferred to a PVDF membrane,
then blotted by primary antibody against CART. Two major sizes
(around 4,10 kDa) of CART peptides were strongly detected in
hypothalamus and pituitary.
(TIF)
Figure S2 Purified CART fusion proteins were recog-
nized by CART-antibody. Fusion proteins were isolated from
bacteria and 2 mg of each protein was run on a 10% SDS-PAGE
gel and Western blot was performed using specific CART-
antibody.
(TIF)
Figure S3 A structure change of TAT-EGFP-CART under
reducing conditions confirmed the fact that original key
feature of CART exists in the fusion protein. A cysteine
reactivity assay using a small maleimide reagent (,500 Da added
per free thiol) shows that TAT-EGFP no significant molecular
weight changes (A); however TAT-EGFP-CART fusion proteins
into a reduced form upon incubation with the reducing agent
dithiothreitol (DTT) (B), demonstrating that the redox of CART
functions (systeines-disulfides change) in the TAT-EGFP-CART
fusion proteins.
(TIF)
Figure S4 TAT-EGFP-CART prevents mitochondrial
dysfunction after oxygen-glucose deprivation in primary
cultured cortical neurons. TAT-EGFP-CART or TAT-
EGFP was added at 0.2 nM concentration 30 min prior to 2 hr
OGD, and mitochondria extracted at 24 hr after OGD. Complex
II activity in mitochondrial extract was measured spectrophoto-
metrically at 595 by 2, 6-dichloroindiphenol (DCIP) reduction
after the addition of Coenzyme Q at 3 min.
(TIF)
Figure S5 Mitochondrial DNAs were amplified by long
template PCR. Total DNA was isolated from differently treated
HEK cells and PCR was performed using specific human
mitochondrial primers and Expand 20 kb DNA amplification
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density), lanes 3 and 4, HEK cells treated with H2O2 for 30 min
(91% of control) and 60 min (22% of control).
(TIF)
Figure S6 Confocal imaging of TAT-EGFP-CART in live
cells shows CART fusion proteins preferentially local-
ized into mitochondria comparing with TAT-EGFP
control. Cultured HEK293 cells were treated overnight with
8 mg/ml of TAT-EGFP-CART or TAT-EGFP fusion proteins as
indicated, and then treated with 50 nM of MitoTracker Red
CMXRos for 30 min. Living cells were analyzed by a confocal
microscopy. Top row, confocal fluorescence images depict cells
treated with TAT-EGFP-CART fusion proteins; and bottom row,
confocal fluorescence images depict cells treated with vehicle
TAT-EGFP fusion proteins. Cells in panels A and D show GFP
(green), cells in panels B and E show mitochondria (red), and
panels C and F are merged images (yellow). Pixels containing
fluorescence for both GFP and the red MitoTracker appear as
yellow in the merged images. Scale bars: 9.95 mm (A–C) and
18.8 mm (D–F).
(TIF)
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